PT941116E - Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega - Google Patents

Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega

Info

Publication number
PT941116E
PT941116E PT97910563T PT97910563T PT941116E PT 941116 E PT941116 E PT 941116E PT 97910563 T PT97910563 T PT 97910563T PT 97910563 T PT97910563 T PT 97910563T PT 941116 E PT941116 E PT 941116E
Authority
PT
Portugal
Prior art keywords
prevention
treatment
manufacture
delivery device
medicinal product
Prior art date
Application number
PT97910563T
Other languages
English (en)
Portuguese (pt)
Inventor
Martin John Francis
Stephen G E Barker
Ylae-Herttuala Seppo Un Kuopio
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622852.3A external-priority patent/GB9622852D0/en
Priority claimed from GBGB9709494.0A external-priority patent/GB9709494D0/en
Priority claimed from GBGB9717791.9A external-priority patent/GB9717791D0/en
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of PT941116E publication Critical patent/PT941116E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PT97910563T 1996-11-01 1997-11-03 Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega PT941116E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9622852.3A GB9622852D0 (en) 1996-11-01 1996-11-01 Treatment of intimal hyperplasma
GBGB9709494.0A GB9709494D0 (en) 1997-05-09 1997-05-09 Delivery device and method
GBGB9717791.9A GB9717791D0 (en) 1997-08-21 1997-08-21 Treatment of intimal hyperplasia

Publications (1)

Publication Number Publication Date
PT941116E true PT941116E (pt) 2005-05-31

Family

ID=27268562

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97910563T PT941116E (pt) 1996-11-01 1997-11-03 Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega

Country Status (14)

Country Link
US (1) US7320679B2 (https=)
EP (2) EP0941116B1 (https=)
JP (3) JP2001503755A (https=)
KR (1) KR100695590B1 (https=)
AT (1) ATE287271T1 (https=)
AU (1) AU729420B2 (https=)
CA (1) CA2270286C (https=)
DE (1) DE69732304T2 (https=)
ES (1) ES2235227T3 (https=)
HU (1) HU223957B1 (https=)
NO (1) NO326303B1 (https=)
PL (1) PL189744B1 (https=)
PT (1) PT941116E (https=)
WO (1) WO1998020027A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
DE69821011T3 (de) * 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
GB9809082D0 (en) 1998-04-28 1998-06-24 Eurogene Limited Delivery device
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
IL145834A0 (en) * 1999-04-26 2002-07-25 Aventis Pharma Sa Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
FR2792531B1 (fr) * 1999-04-26 2003-01-31 Aventis Pharma Sa Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
JP2003509463A (ja) * 1999-09-23 2003-03-11 アン−ゴー−ジェン インコーポレーテッド 肺系のための細胞ベースの遺伝子治療
IL148674A0 (en) * 1999-11-02 2002-09-12 Genentech Inc Modulation of enos activity and therapeutic uses thereof
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
SE0000285D0 (sv) * 1999-12-07 2000-01-31 Mika Lahtinen Medical implant
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
WO2003003948A1 (en) * 2001-07-06 2003-01-16 Tricardia, L.L.C. Anti-arrhythmia devices and methods of use
SE0102578L (sv) * 2001-07-20 2003-01-21 Oeyvind Reitan Förändring av en stents egenskaper för att förhindra restenos
US20060154884A1 (en) * 2003-06-18 2006-07-13 Arnd Buchwald Use of a vegf receptor gener or gene product
GB0515140D0 (en) 2005-07-22 2005-08-31 Ark Therapeutics Ltd Therapeutic device
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
TWI428143B (zh) * 2006-01-18 2014-03-01 Gen Hospital Corp 增加淋巴功能之方法
US8721711B2 (en) 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
WO2009079388A2 (en) * 2007-12-14 2009-06-25 Oregon Health & Science University Drug delivery cuff
DE102008002396A1 (de) 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Implantierbares Wirkstoffreservoir und Vorrichtung mit einem implantierbaren Wirkstoffreservoir
CN108310396B (zh) * 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
WO2013135266A1 (en) 2012-03-12 2013-09-19 Gemvax As Treatment of non-small cell lung carcinoma by active immunotherapy
CA2880808C (en) 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
JP6431850B2 (ja) 2013-01-09 2018-11-28 ユナイテッド セラピューティクス コーポレイション プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置
ES2927406T3 (es) 2016-10-24 2022-11-04 United Therapeutics Corp Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil
JP7791715B2 (ja) * 2019-04-05 2025-12-24 韓國セラミック技術院 Ｃｓｑ－タグを用いたタンパク質の発現及び精製方法
IT201900012537A1 (it) * 2019-07-22 2021-01-22 Milano Politecnico Dispositivo di condizionamento per condizionare un tratto esposto di un vaso sanguigno e metodo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
JPS56122317A (en) * 1980-02-29 1981-09-25 Koken:Kk Drug transporting material and its preparation
US5326568A (en) * 1991-05-03 1994-07-05 Giampapa Vincent C Method of tissue-specific delivery
US5201728A (en) * 1991-05-03 1993-04-13 Giampapa Vincent C Subcutaneous implantable multiple-agent delivery system
US5399352A (en) * 1993-04-14 1995-03-21 Emory University Device for local drug delivery and methods for using the same
EP0702518B1 (en) * 1993-06-11 2003-04-02 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5653744A (en) * 1995-04-27 1997-08-05 Khouri Biomedical Research, Inc. Device and method for vascular anastomosis
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor

Also Published As

Publication number Publication date
DE69732304D1 (de) 2005-02-24
JP4783797B2 (ja) 2011-09-28
WO1998020027A2 (en) 1998-05-14
WO1998020027A3 (en) 1998-10-08
AU729420B2 (en) 2001-02-01
HUP9902867A3 (en) 2001-12-28
KR20000052999A (ko) 2000-08-25
US20030225020A1 (en) 2003-12-04
HU223957B1 (hu) 2005-03-29
NO992106D0 (no) 1999-04-30
NO326303B1 (no) 2008-11-03
AU4790697A (en) 1998-05-29
CA2270286C (en) 2009-03-03
JP2008155036A (ja) 2008-07-10
EP0941116A2 (en) 1999-09-15
NO992106L (no) 1999-06-30
JP2012031196A (ja) 2012-02-16
DE69732304T2 (de) 2005-06-02
EP0941116B1 (en) 2005-01-19
KR100695590B1 (ko) 2007-03-14
ES2235227T3 (es) 2005-07-01
JP2001503755A (ja) 2001-03-21
EP1488761A1 (en) 2004-12-22
PL333272A1 (en) 1999-11-22
ATE287271T1 (de) 2005-02-15
CA2270286A1 (en) 1998-05-14
PL189744B1 (pl) 2005-09-30
US7320679B2 (en) 2008-01-22
HUP9902867A2 (hu) 1999-12-28
HK1108845A1 (zh) 2008-05-23

Similar Documents

Publication Publication Date Title
PT941116E (pt) Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
WO2004049918A3 (en) A system for administering a combination of therapies to a body lumen
ATE429904T1 (de) Topisch anwendbare arzneipräparate und verfahren zur behandlung
DE3374300D1 (en) Stabilized activated oxygen and medicaments containing this stabilized activated oxygen
EP0244080A3 (en) Medicament for the treatment of obesity
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
CA2390377A1 (en) Method and apparatus for delivery of controlled doses of therapeutic drugs in endoluminal procedures
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
DE60027921D1 (de) Vorrichtung zur gleichzeitigen verabreichung von gasen und medikamenten
DK662887A (da) Fladeformigt terapeutisk system, fremgangsmaade til fremstilling deraf og anvendelse deraf
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
EP1539225B1 (en) Apparatus and methods for use in enzymatic escharotomy in burn induced compartment syndrome
ATE178208T1 (de) Capsaicin enthaltendes arzneimittel zur behandlung chronischer rhinopathie
Aeikens et al. Initial experience with local anesthesia in extracorporeal shock wave lithotripsy
ID23176A (id) Metoda untuk mengobati gangguan pembuluh darah
SE9101341D0 (sv) New medicinal use
ATE274935T1 (de) Gerät zur instillation oder injektion von arzneimitteln
AU6102801A (en) Method of preventing or treating diabetes
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
Andreev et al. Treatment of diffused laryngeal and pharyngeal cancer with preoperative radiotherapy in combination with radiation-modifying agents
Peterson DepartmentConsultation| Annals of Emergency Medicine-Volume 16, Issue 7
UA5715C2 (uk) Спосіб індивідуального підбору оптимальних доз судинорозширюючих препаратів та пристрій для його здійснення